A Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Cardinal Study
- Sponsors Bioverativ
- 06 Mar 2018 According to a Bioverativ media release, first patient has been dosed in this trial.
- 10 Jan 2018 Status changed from not yet recruiting to recruiting.
- 16 Nov 2017 Status changed from planning to not yet recruiting.